Payment overview · 2025
General Payments
$752.19
39 reported records · 20 companies
Healthcare provider profile · identity verified
Girish S Amin, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology · BRICK, NJ · NPI 1720071731
Verified facts
What the public records show
CMS Open Payments records show Girish S Amin, MD received $752.19 in general payments during 2025 across 39 reported records.
Gilead Sciences, Inc. accounted for 26.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jakafi.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Xtandi as an associated drug or biological on 11345 records involving 5418 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Xtandi by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Eliquis by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REBLOZYL as an associated drug or biological on 1732 records involving 943 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Reblozyl by this doctor in 2024.
Incyte Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JAKAFI as an associated drug or biological on 14854 records involving 6477 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Jakafi by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IBRANCE as an associated drug or biological on 11505 records involving 4934 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Ibrance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 19368 records involving 7657 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Xtandi by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $201.55 | 26.8% | 10 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $157.50 | 20.9% | 7 | 2025 |
| Pharmacosmos Therapeutics Inc. | Unresolved — no canonical attribution shown | $37.54 | 5.0% | 2 | 2025 |
| Telix Pharmaceuticals | Unresolved — no canonical attribution shown | $34.51 | 4.6% | 2 | 2025 |
| Geron Corporation | Unresolved — no canonical attribution shown | $33.05 | 4.4% | 2 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $32.99 | 4.4% | 2 | 2025 |
| Aveo Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.12 | 3.7% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $22.63 | 3.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.31 | 2.8% | 1 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $18.99 | 2.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $17.53 | 2.3% | 1 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $17.33 | 2.3% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $17.17 | 2.3% | 1 | 2025 |
| Exelixis Inc. | Unresolved — no canonical attribution shown | $17.07 | 2.3% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $16.99 | 2.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.46 | 2.2% | 1 | 2025 |
| Blueprint Medicines Corporation | Unresolved — no canonical attribution shown | $16.16 | 2.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.91 | 2.1% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.81 | 2.1% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $13.57 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $494.70 | 31 |
| Education | $257.49 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $201.55 | 10 | 2025 |
Source payment records
|
|||||
| Enhertu Normalized: enhertu |
Drug | Daiichi Sankyo Inc. | $157.50 | 7 | 2025 |
Source payment records
|
|||||
| MONOFERRIC Normalized: monoferric |
Drug | Pharmacosmos Therapeutics Inc. | $37.54 | 2 | 2025 |
Source payment records
|
|||||
| ILLUCCIX Normalized: illuccix |
Drug | Telix Pharmaceuticals | $34.51 | 2 | 2025 |
Source payment records
|
|||||
| RYTELO Normalized: rytelo |
Drug | Geron Corporation | $33.05 | 2 | 2025 |
Source payment records
|
|||||
| LYNOZYFIC Normalized: lynozyfic |
Biological | Regeneron Healthcare Solutions, Inc. | $32.99 | 2 | 2025 |
Source payment records
|
|||||
| FOTIVDA Normalized: fotivda |
Drug | Aveo Pharmaceuticals, Inc. | $28.12 | 1 | 2025 |
Source payment records
|
|||||
| CERDELGA Normalized: cerdelga |
Drug | GENZYME CORPORATION | $22.63 | 1 | 2025 |
Source payment records
|
|||||
| CEREZYME Normalized: cerezyme |
Biological | GENZYME CORPORATION | $22.63 | 1 | 2025 |
Source payment records
|
|||||
| Nubeqa Normalized: nubeqa |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.31 | 1 | 2025 |
Source payment records
|
|||||
| Stivarga Normalized: stivarga |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.31 | 1 | 2025 |
Source payment records
|
|||||
| Vitrakvi Normalized: vitrakvi |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.31 | 1 | 2025 |
Source payment records
|
|||||
| Onivyde Normalized: onivyde |
Drug | Ipsen Biopharmaceuticals, Inc | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| PLUVICTO Normalized: pluvicto |
Drug | Novartis Pharmaceuticals Corporation | $17.53 | 1 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $17.33 | 1 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | Sumitomo Pharma America, Inc. | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| CABOMETYX Normalized: cabometyx |
Drug | Exelixis Inc. | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $16.99 | 1 | 2025 |
Source payment records
|
|||||
| PADCEV Normalized: padcev |
Biological | PFIZER INC. | $16.46 | 1 | 2025 |
Source payment records
|
|||||
| AYVAKIT Normalized: ayvakit |
Drug | Blueprint Medicines Corporation | $16.16 | 1 | 2025 |
Source payment records
|
|||||
| Xospata Normalized: xospata |
Drug | Astellas Pharma US Inc | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | E.R. Squibb & Sons, L.L.C. | $13.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JAKAFI jakafi |
2025 | Jakafi | 2024 | 82 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Xtandi open payments reported associated product |
CMS Open Payments — General Payments 11345 supporting records · 5418 recipient NPIs · example record 1238560686 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
90 | 24 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | REBLOZYL open payments reported associated product |
CMS Open Payments — General Payments 1732 supporting records · 943 recipient NPIs · example record 1184377805 |
Reblozyl · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Incyte Corporation Exact reporting entity; no affiliate inference |
2025 | JAKAFI open payments reported associated product |
CMS Open Payments — General Payments 14854 supporting records · 6477 recipient NPIs · example record 1225959940 |
Jakafi · 2024 Exact normalized brand match · 1 Part D row |
82 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
90 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | IBRANCE open payments reported associated product |
CMS Open Payments — General Payments 11505 supporting records · 4934 recipient NPIs · example record 1228794164 |
Ibrance · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 19368 supporting records · 7657 recipient NPIs · example record 1228794230 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydroxyurea | Hydroxyurea | 150 | 47 |
| Prednisone | Prednisone | 118 | 46 |
| Letrozole | Letrozole | 103 | 36 |
| Eliquis | Apixaban | 90 | 24 |
| Jakafi | Ruxolitinib Phosphate | 82 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 82 | 50 |
| Abiraterone Acetate | Abiraterone Acetate | 81 | 11 |
| Acyclovir | Acyclovir | 76 | 22 |
| Allopurinol | Allopurinol | 44 | 14 |
| Brukinsa | Zanubrutinib | 37 | suppressed |
| Gabapentin | Gabapentin | 37 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Dexamethasone | Dexamethasone | 34 | 20 |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 31 | 22 |
| Oxycodone Hcl | Oxycodone Hcl | 31 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 31 | suppressed |
| Imatinib Mesylate | Imatinib Mesylate | 30 | suppressed |
| Lenalidomide | Lenalidomide | 28 | suppressed |
| Ojjaara | Momelotinib Dihydrochloride | 28 | suppressed |
| Xtandi | Enzalutamide | 28 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | 13 |
| Tamoxifen Citrate | Tamoxifen Citrate | 27 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 18 |
| Pomalyst | Pomalidomide | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | suppressed |
| Alprazolam | Alprazolam | 20 | suppressed |
| Methotrexate | Methotrexate Sodium | 20 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 19 | suppressed |
| Ibrance | Palbociclib | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 13 |
| Lynparza | Olaparib | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 15 |
| Reblozyl | Luspatercept-Aamt | 17 | suppressed |
| Bicalutamide | Bicalutamide | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 16 | suppressed |
| Venclexta | Venetoclax | 16 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 13 | suppressed |
| Alecensa | Alectinib Hcl | 12 | suppressed |
| Imbruvica | Ibrutinib | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Revlimid | Lenalidomide | 12 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 11 | suppressed |
| Potassium Chloride | Potassium Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $752.19 · 39 records | Gilead Sciences, Inc. | AYVAKIT, CABOMETYX, CERDELGA, CEREZYME, Enhertu, FOTIVDA, ILLUCCIX, JAKAFI, LYNOZYFIC, Lenvima, MONOFERRIC, Nubeqa, OPDIVO, ORGOVYX, Onivyde, PADCEV, PLUVICTO, RYTELO, Stivarga, Trodelvy, Vitrakvi, Xospata | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jakafi play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error